CN114588105A - Decoquinate solution and preparation method thereof - Google Patents
Decoquinate solution and preparation method thereof Download PDFInfo
- Publication number
- CN114588105A CN114588105A CN202110261833.3A CN202110261833A CN114588105A CN 114588105 A CN114588105 A CN 114588105A CN 202110261833 A CN202110261833 A CN 202110261833A CN 114588105 A CN114588105 A CN 114588105A
- Authority
- CN
- China
- Prior art keywords
- decoquinate
- solution
- cosolvent
- solvent
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical compound N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960001878 decoquinate Drugs 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000006184 cosolvent Substances 0.000 claims abstract description 28
- 239000000945 filler Substances 0.000 claims abstract description 27
- 238000003756 stirring Methods 0.000 claims abstract description 21
- 238000010438 heat treatment Methods 0.000 claims abstract description 16
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000001816 cooling Methods 0.000 claims abstract description 8
- 238000011049 filling Methods 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- -1 polyoxyethylene Polymers 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 15
- 239000004359 castor oil Substances 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 10
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 125000006838 isophorone group Chemical group 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims 1
- 229940113088 dimethylacetamide Drugs 0.000 abstract description 11
- 241000224483 Coccidia Species 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 244000144977 poultry Species 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 7
- 235000004443 Ricinus communis Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 230000001165 anti-coccidial effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a decoquinate solution which comprises 1-10% of decoquinate, 20-75% of dimethylacetamide, 10-35% of a first filling agent, 5-10% of a second filling agent, 3-20% of a first cosolvent and 3-20% of a second cosolvent. The invention also relates to a preparation method of the decoquinate solution, which comprises the steps of mixing dimethyl acetamide, a first filling agent and a first cosolvent, and heating to a first temperature of 40-70 ℃; adding decoquinate, stirring until the decoquinate is dissolved, adding a second filling agent, and heating to a second temperature of 50-80 ℃; adding a second cosolvent, and uniformly stirring; naturally cooling the prepared solution to room temperature, fine filtering and filling. The invention has safe production process, simple process and preparation under the conventional environment. Has good effect of preventing coccidian diseases of poultry, has lower cost compared with other coccidian-resistant medicines, is not degraded in water, and has good compliance when being taken.
Description
Technical Field
The invention belongs to the field of veterinary drug preparations, and particularly provides decoquinate solution and a preparation method thereof.
Background
Decoquinate is an anticoccidial medicament widely used in veterinary clinic at present, and has good treatment effect on poultry coccidiosis. The decoquinate acts on the asexual propagation stage of the coccidia, can be fused into the coccidia spore cells to inhibit cell propagation, so that the development of the coccidia is stopped, and the decoquinate acts at the early stage of the coccidia to avoid the attack of poultry. The medicine is absorbed quickly and reaches effective concentration within several hours.
The poultry drinking mode is adopted for convenient and quick administration. However, the problem of decoquinate is that decoquinate is difficult to dissolve in water, which severely limits the clinical application of the medicine.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a decyloxypan vinegar solution as an anticoccidial medicament and a preparation method thereof. The technical method of the invention can highly disperse decoquinate in drinking water, overcomes the defect that the decoquinate is insoluble in water, and has important significance in the aspect of drinking water administration.
The invention adopts the following technical scheme:
according to one aspect of the present invention, there is provided a decoquinate solution comprising 1-10% of decoquinate, 20-75% of dimethylacetamide, 10-35% of a first filler, 5-10% of a second filler, 3-20% of a first co-solvent, and 3-20% of a second co-solvent.
According to certain embodiments of the invention, the decoquinate solution comprises decoquinate 1% -10%, such as decoquinate 1% -8%, 1% -6%, 1% -3%, 3% -10%, 6% -8%, or 8% -10%. According to certain embodiments of the invention, the decoquinate solution comprises decoquinate 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%.
According to certain embodiments of the invention, the decoquinate solution comprises 20% -75% dimethylacetamide, such as 20% -70%, 20% -60%, 20% -50%, 20% -40%, 20% -30%, 30% -75%, 30% -70%, 30% -60%, 30% -50%, 30% -40%, 40% -75%, 40% -70%, 40% -60%, 40% -50%, 50% -75%, 50% -70%, 50% -60%, 60% -75%, 60% -70%, or 70% -75%. According to certain embodiments of the invention, the decoquinate solution comprises 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75% dimethylacetamide.
According to certain embodiments of the invention, the first co-solvent is selected from polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80.
According to certain embodiments of the invention, the first co-solvent is selected from one or more of polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80. According to certain embodiments of the invention, the first co-solvent is a mixture of two or three of polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80 in any ratio.
According to certain embodiments of the invention, the second co-solvent is selected from polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80.
According to certain embodiments of the invention, the second co-solvent is selected from one or more of polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80. According to certain embodiments of the invention, the second co-solvent is a mixture of two or three of polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80 in any ratio.
According to certain embodiments of the invention, the first co-solvent is polyvinylpyrrolidone K30 and the second co-solvent is polyoxyethylene hydrogenated castor oil 60.
According to certain embodiments of the invention, the first co-solvent is 3-20%, e.g., 3-15%, 3-10%, 3-5%, 5-20%, 5-15%, 5-10%, 10-20%, 10-15%, or 15-20%. According to certain embodiments of the invention, the first co-solvent is 3%, 4%, 5%, 67%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%.
According to certain embodiments of the invention, the second co-solvent is 3-20%, e.g., 3-15%, 3-10%, 3-5%, 5-20%, 5-15%, 5-10%, 10-20%, 10-15%, or 15-20%. According to certain embodiments of the invention, the second co-solvent is 3%, 4%, 5%, 67%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%.
According to certain embodiments of the present invention, the first filler is selected from the group consisting of absolute ethanol, isophorone, propylene glycol, glycerol, or isopropanol.
According to certain embodiments of the present invention, the first filler is selected from one or more of anhydrous ethanol, isophorone, propylene glycol, glycerol, or isopropanol. According to some embodiments of the invention, the first filler is a mixture of a plurality of anhydrous ethanol, isophorone, propylene glycol, glycerol, or isopropanol in any proportion.
According to certain embodiments of the present invention, the second filler is selected from the group consisting of absolute ethanol, isophorone, propylene glycol, glycerol, or isopropanol.
According to certain embodiments of the present invention, the second filler is selected from one or more of anhydrous ethanol, isophorone, propylene glycol, glycerol, or isopropanol. According to some embodiments of the invention, the second filler is a mixture of a plurality of anhydrous ethanol, isophorone, propylene glycol, glycerol, or isopropanol in any proportion.
According to certain embodiments of the invention, the first filler is absolute ethanol and the second filler is isophorone.
According to certain embodiments of the invention, the first filler is 10-35%, such as 10-30%, 10-25%, 10-20%, 10-15%, 15-35%, 15-30%, 15-25%, 15-20%, 20-35%, 20-30%, 20-25%, 25-35%, 25-30% or 30-35%. According to certain embodiments of the invention, the first filler is 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29% or 30%.
According to certain embodiments of the invention, the second filler is 5-10%, such as 10-30%, 10-25%, 10-20%, 10-15%, 15-35%, 15-30%, 15-25%, 15-20%, 20-35%, 20-30%, 20-25%, 25-35%, 25-30%, or 30-35%. According to certain embodiments of the invention, the second filler is 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29% or 30%.
According to one aspect of the invention, the invention provides a preparation method of decoquinate solution, wherein the method comprises the steps of mixing dimethyl acetamide, a first filling agent and a first cosolvent, and heating to a first temperature of 40-70 ℃; adding decoquinate and stirring until the decoquinate is dissolved; then adding a second filling agent, and heating to a second temperature of 50-80 ℃; adding a second cosolvent, and uniformly stirring; naturally cooling the prepared solution to room temperature, fine filtering and filling.
According to certain embodiments of the invention, the first temperature is 40 ℃ to 70 ℃, e.g., 40 ℃ to 60 ℃, 40 ℃ to 50 ℃, 50 ℃ to 70 ℃, 50 ℃ to 60 ℃, or 60 ℃ to 70 ℃. According to some embodiments of the invention, the first temperature is 40 ℃, 45 ℃, 50 ℃, 55 ℃, 60 ℃, 65 ℃ or 70 ℃.
According to certain embodiments of the invention, the first temperature is 50 ℃ to 80 ℃, such as 50 ℃ to 70 ℃, 50 ℃ to 60 ℃, 60 ℃ to 80 ℃, 60 ℃ to 70 ℃, or 70 ℃ to 80 ℃.
Detailed Description
The present invention is further described in detail below with reference to specific examples.
Example 1: decoquinate solution
Mixing 75% of dimethylacetamide and 13% of absolute ethyl alcohol, and heating to 50 ℃; adding decoquinate 1%, and stirring to dissolve; then adding polyvinylpyrrolidone K303% and isophorone 5%, and heating to 60 ℃; adding 603% polyoxyethylene hydrogenated castor while hot, and stirring. Naturally cooling the solution to be prepared to room temperature; stirring uniformly, fine filtering and filling.
Example 2: decoquinate solution
Mixing dimethylacetamide 64% and absolute ethyl alcohol 20%, and heating to 50 ℃; adding decoquinate 2%, and stirring to dissolve; then adding polyvinylpyrrolidone K304% and isophorone 6%, and heating to 60 ℃; adding 604% polyoxyethylene hydrogenated castor while it is hot, and stirring. Naturally cooling the solution to be prepared to room temperature; stirring uniformly, fine filtering and filling.
Example 3: decoquinate solution
Mixing 55% of dimethylacetamide and 25% of absolute ethyl alcohol, and heating to 55 ℃; adding decoquinate 2%, and stirring until the decoquinate is dissolved; then adding polyvinylpyrrolidone K305% and isophorone 7%, and heating to 65 ℃; adding 606% polyoxyethylene hydrogenated castor while it is hot, and stirring well. Naturally cooling the solution to be prepared to room temperature; stirring uniformly, fine filtering and filling.
Example 4: decoquinate solution
Mixing 39% of dimethylacetamide and 35% of absolute ethyl alcohol, and heating to 55 ℃; adding decoquinate 3%, and stirring until the decoquinate is dissolved; then adding polyvinylpyrrolidone K305% and isophorone 8%, and heating to 65 ℃; adding polyoxyethylene hydrogenated castor 6010% while the mixture is hot, and stirring uniformly. Naturally cooling the solution to be prepared to room temperature; stirring uniformly, fine filtering and filling.
Example 5: decoquinate solution
Mixing dimethylacetamide 42% and absolute ethyl alcohol 30%, and heating to 60 ℃; adding decoquinate 3%, and stirring until the decoquinate is dissolved; then adding polyvinylpyrrolidone K306 and isophorone 10%, and heating to 70 ℃; adding polyoxyethylene hydrogenated castor 609 percent while the mixture is hot, and stirring the mixture evenly. Naturally cooling the solution to be prepared to room temperature; stirring uniformly, fine filtering and filling.
Example 6: sample stability test
The control was a 3% solution of decoquinate manufactured by Shandong Jianmu biopharmaceutical, Inc., lot number 201905211. This is a commercially available product that meets the national veterinary quality standards as a positive control.
Stability tests were performed on the decoquinate solutions prepared according to the methods in examples 1-5, as well as on the control.
The sample was stored in a refrigerated environment at 4 ℃ and a freezing environment at-20 ℃ for 10 days, and the state of the sample was observed for 0 day and 10 days, respectively, and the results are shown in Table 1.
TABLE 1 stability survey table
From the above table, it can be seen that the liquid preparation is free from precipitation at low temperature and is stable in state. This example demonstrates that the products of examples 1-5 of the present invention have the same stability as the commercial product.
The foregoing is merely a preferred embodiment of the invention and variations and modifications may be made without departing from the general inventive concept, which should be construed as broadly as the invention.
Claims (8)
1. The decoquinate solution comprises 1% -10% of decoquinate, 20% -75% of dimethylacetamide, 10% -35% of a first filling agent, 5% -10% of a second filling agent, 3% -20% of a first cosolvent and 3% -20% of a second cosolvent.
2. The decoquinate solution of claim 1, wherein the first co-solvent is selected from polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80.
3. The decoquinate solution of claim 1, wherein the second co-solvent is selected from polyoxyethylene hydrogenated castor oil 60, polyvinylpyrrolidone K30, or tween 80.
4. The decoquinate solution of claim 1, wherein the first co-solvent is polyvinylpyrrolidone K30 and the second co-solvent is polyoxyethylene hydrogenated castor oil 60.
5. The decoquinate solution of claim 1, wherein the first filler is selected from the group consisting of absolute ethanol, isophorone, propylene glycol, glycerol, and isopropanol.
6. The decoquinate solution of claim 1, wherein the second filler is selected from the group consisting of absolute ethanol, isophorone, propylene glycol, glycerol, and isopropanol.
7. The decoquinate solution of claim 1, wherein the first filler is absolute ethanol and the second filler is isophorone.
8. A process for preparing the decoquinate solution of any one of claims 1-7, wherein the process comprises mixing dimethylacetamide, a first bulking agent, a first co-solvent, and heating to a first temperature of 40 ℃ to 70 ℃; adding decoquinate, stirring until the decoquinate is dissolved, adding a second filling agent, and heating to a second temperature of 50-80 ℃; adding a second cosolvent, and uniformly stirring; naturally cooling the prepared solution to room temperature, fine filtering and filling.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011395106 | 2020-12-03 | ||
| CN2020113951068 | 2020-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114588105A true CN114588105A (en) | 2022-06-07 |
Family
ID=81814253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110261833.3A Pending CN114588105A (en) | 2020-12-03 | 2021-03-10 | Decoquinate solution and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114588105A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129371A (en) * | 2007-08-26 | 2008-02-27 | 青岛康地恩实业有限公司 | Novel against-coccidia pharmaceutical formulation and technique of preparing the same |
| CN104288098A (en) * | 2014-09-19 | 2015-01-21 | 中农颖泰林州生物科园有限公司 | Preparation method of decoquinate solution |
| CN108014073A (en) * | 2016-11-04 | 2018-05-11 | 施瑞客（天津）生物技术有限公司 | A kind of coccidiostat decoquinate ester solution and preparation method thereof |
| CN110075065A (en) * | 2019-06-04 | 2019-08-02 | 河南健恒动物药业有限公司 | A kind of coccidiostat decoquinate ester solution and preparation method thereof |
-
2021
- 2021-03-10 CN CN202110261833.3A patent/CN114588105A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129371A (en) * | 2007-08-26 | 2008-02-27 | 青岛康地恩实业有限公司 | Novel against-coccidia pharmaceutical formulation and technique of preparing the same |
| CN104288098A (en) * | 2014-09-19 | 2015-01-21 | 中农颖泰林州生物科园有限公司 | Preparation method of decoquinate solution |
| CN108014073A (en) * | 2016-11-04 | 2018-05-11 | 施瑞客（天津）生物技术有限公司 | A kind of coccidiostat decoquinate ester solution and preparation method thereof |
| CN110075065A (en) * | 2019-06-04 | 2019-08-02 | 河南健恒动物药业有限公司 | A kind of coccidiostat decoquinate ester solution and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王道 等: "环境有害化学品实用手册", vol. 1, 31 December 2007, 中国环境科学出版社, pages: 451 - 452 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2674154A2 (en) | Sildenafil-free base-containing film preparation and method for producing same | |
| WO2023087578A1 (en) | Urapidil hydrochloride injection and preparation method therefor | |
| CN114588105A (en) | Decoquinate solution and preparation method thereof | |
| CN107661294B (en) | Anti-hypertension drug fat emulsion injection and preparation method thereof | |
| KR20140072716A (en) | Film having improved haze | |
| JPH0558914A (en) | Skin external preparation | |
| CN113520994A (en) | Mupirocin ointment preparation | |
| CN114191388B (en) | Preparation method of carbetocin preparation | |
| CN105476954B (en) | A kind of lomefloxacin hydrochloride injection and preparation method | |
| CN113633610A (en) | Methotrexate injection and preparation method thereof | |
| CN103720666B (en) | A kind of preparation method of injection bortezomib lyophilized formulations | |
| CN114504548B (en) | Ointment and preparation method thereof | |
| CN108403619B (en) | Medicinal gel preparation for treating skin burn caused by hydrofluoric acid | |
| EP3986378A1 (en) | Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients | |
| CN112717119B (en) | Cetrorelix pharmaceutical composition and preparation method thereof | |
| JP5440635B2 (en) | Eye drops | |
| CN113750041A (en) | Dexamethasone sodium phosphate liquid preparation and preparation method thereof | |
| CN111658602A (en) | Preparation method of stable Kelibuo ointment | |
| CN115590814B (en) | Phentolamine mesylate injection and preparation method thereof | |
| US3702364A (en) | Stabilized chloramphenicol composition | |
| CN116270434A (en) | Mopirocin ointment and preparation method thereof | |
| CN112274484B (en) | Process treatment method for improving stability of terbutaline sulfate atomized liquid | |
| CN115487153B (en) | Method for protecting crystal forms of compounds | |
| CN117338706A (en) | Minoxidil external solution and preparation method thereof | |
| CN104557585A (en) | Tetracaine hydrochloride crystal, composition containing tetracaine hydrochloride and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |